Vasohibin attenuates bleomycin induced pulmonary fibrosis via inhibition of angiogenesis in mice

References

• El-Chemaly S, Malide D, Zudaire E, et al Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci USA 2009; 106: 3958–3963.
   PubMedGoogle Scholar
• Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: Focus on TGFbeta signaling and the myofibroblast. Curr Med Chem 2009; 16: 1400–1417.
   PubMed Web of Science ®Google Scholar
• Andersson-Sjoland A, de Alba CG, Nihlberg K, et al Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 2129–2140.
   PubMed Web of Science ®Google Scholar
• Khalil N, Xu YD, O'Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 2005; 280: 43000–43009.
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: A potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res 2007; 24: 819–841.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2285–2287.
   PubMed Web of Science ®Google Scholar
• Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Resp Med 2008; 102: 1355–1359.
   PubMed Web of Science ®Google Scholar
• Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: A systematic review. Eur J Int Med 2008; 19: 227–235.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Resp Crit Care Med 2000; 161: 646–664.
   PubMed Web of Science ®Google Scholar
• Rochat T, Leuenberger P. Pneumology. Treatment of idiopathic pulmonary fibrosis: Hopes and disappointment. (French). Rev Med Suisse 2005; 1: 153–154, 156–8.
   PubMedGoogle Scholar
• Douglas IS, Nicolls MR. Chemokine-mediated angiogenesis: An essential link in the evolution of airway fibrosis? J Clin Invest 2005; 115: 1133–1136.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000; 9: 413–418.
   PubMedGoogle Scholar
• Hamada N, Kuwano K, Yamada M, et al Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005; 175: 1224–1231.
   PubMed Web of Science ®Google Scholar
• Huerta-Yepez S, Baay-Guzman GJ, Garcia-Zepeda R, et al 2-methoxyestradiol (2-me) reduces the airway inflammation and remodeling in an experimental mouse model. Clin Immunol 2008; 129: 313–324.
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Tzanakis N, Tzortzaki EG, et al Different angiogenic cxc chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther 2008; 21: 840–844.
   PubMedGoogle Scholar
• Voelkel NF, Douglas IS, Nicolls M. Angiogenesis in chronic lung disease. Chest 2007; 131: 874–879.
   PubMedGoogle Scholar
• Bauer SM, Bauer RJ, Liu ZJ, Chen H, Goldstein L, Velazquez OC. Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J Vasc Surg 2005; 41: 699–707.
   PubMed Web of Science ®Google Scholar
• Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (vegf)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 1998; 177: 439–452.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Vasohibin: The feedback on a new inhibitor of angiogenesis. J Clin Invest 2004; 114: 884–886.
   PubMedGoogle Scholar
• Watanabe K, Hasegawa Y, Yamashita H, et al Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004; 114: 898–907.
   PubMed Web of Science ®Google Scholar
• Wakusawa R, Abe T, Sato H, et al Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes. Am J Ophthalmol 2008; 146: 235–243.
   PubMedGoogle Scholar
• Yamashita H, Abe M, Watanabe K, et al Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Comm 2006; 345: 919–925.
   PubMedGoogle Scholar
• Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440–447.
   PubMed Web of Science ®Google Scholar
• Pan LH, Yamauchi K, Uzuki M, et al Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001; 17: 1220–1227.
   PubMed Web of Science ®Google Scholar
• Henry MT, McMahon K, Mackarel AJ, et al Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J 2002; 20: 1220–1227.
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, et al Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol 2008; 40: 2174–2182.
   PubMed Web of Science ®Google Scholar
• Henke C, Fiegel V, Peterson M, et al Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury. J Clin Invest 1991; 88: 1386–1395.
   PubMed Web of Science ®Google Scholar
• Marinelli WA, Henke CA, Harmon KR, Hertz MI, Bitterman PB. Mechanisms of alveolar fibrosis after acute lung injury. Clin Chest Med 1990; 11: 657–672.
   PubMedGoogle Scholar
• Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963; 18: 225–237.
   PubMedGoogle Scholar
• Keane MP, Arenberg DA, Lynch JP 3rd, et al The cxc chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437–1443.
   PubMed Web of Science ®Google Scholar
• Keane MP, Belperio JA, Moore TA, et al Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999; 162: 5511–5518.
   PubMed Web of Science ®Google Scholar
• Keane MP, Belperio JA, Arenberg DA, et al IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999; 163: 5686–5692.
   PubMed Web of Science ®Google Scholar
• Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. Ena-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2001; 164: 2239–2242.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: A historical review. Gen Pharmacol 2000; 35: 227–231.
   PubMedGoogle Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev 2002; 2: 795–803.
   Google Scholar
• Lord BI. Feedback regulators in normal and tumour tissues. J Cell Sci 1988; 10: 231–242.
   Google Scholar